Schrödinger, a provider of a computational platform used to accelerate drug discovery and materials design, revealed on Friday that it has received a milestone payment from Ono Pharmaceutical Co Ltd.
Ono has used Schrödinger's advanced computational platform to develop novel therapeutic candidates acting on its therapeutic target.
Under the programme, Schrödinger deployed its reaction-based enumeration tools and machine-learning technologies to identify and filter potential ligands for the target under the collaboration. Its physics-based computational assays were then used to predict potency with experimental accuracy. The integration of physics-based molecular simulations with machine learning enabled efficient prioritization of promising therapeutic candidates, reducing the number of compounds that had to be synthesized.
In conjunction, Schrödinger said its research collaborations with leading biotech and pharmaceutical companies around the world have already led to two FDA-approved oncology drugs and several clinical-stage assets. More than two dozen additional programmes across multiple indications are moving through discovery and development.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients